Jiangsu Vcare's VC005 Demonstrated Positive Results in the Phase II Clinical Trial for the Oral Treatment of Ankylosing Spondylitis
Published Time:
2024-07-08 17:50
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) reported positive results from its Phase II clinical trial of VC005 tablets, a second-generation selective JAK1 inhibitor, for the treatment of ankylosing spondylitis (AS).
Efficacy: Low-dose group demonstrated significant improvements in the primary efficacy endpoint compared to placebo, with efficacy comparable to the active comparator tofacitinib. High-dose group showed no worsening of efficacy metrics relative to tofacitinib.
Safety: Overall safety and tolerability were favorable, with no dose-related adverse reactions observed. Combined incidence of Grade 3 or higher TEAEs, TEAEs leading to discontinuation, and SAEs across all dose groups were low, comparable to placebo and significantly lower than tofacitinib.
VC005 tablets are nearing completion of Phase II development in AS, with Phase III trials scheduled to commence in the second half of this year.
About VC005
VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, it reduces inflammatory responses and immune cell activation, positioning it as a promising therapy for inflammatory and autoimmune diseases.
Compared to Upadacitinib (a marketed JAK inhibitor), VC005 exhibits lower JAK2 inhibitory activity (based on in vitro kinase assays), potentially mitigating safety concerns associated with excessive JAK2 inhibition. Oral Tablet formulation of VC005 is currently in Phase II trials for AS and moderate-to-severe AD, both studies demonstrated positive interim results. The topical Gel formulation is now in Phase I for mild-to-moderate AD, with data aligning with project expectations.
About JAK1
The JAK/STAT signaling pathway, mediated by JAK family kinases and downstream STAT transcription factors, plays a critical role in regulating inflammatory and autoimmune diseases such as AS and AD. Current first-generation pan-JAK inhibitors(e.g., Tofacitinib) broadly suppress multiple JAK subtypes, particularly JAK2, leading to significant safety concerns. This has prompted the U.S. FDA to issue black box warnings for such drugs. Second-generation selective JAK1 inhibitors, like VC005, aim to deliver enhanced safety and efficacy, positioning them as superior therapeutic options.
About Ankylosing Spondylitis (AS)
AS is a chronic inflammatory disease primarily affecting the sacroiliac joints, spine, paravertebral soft tissues, and peripheral joints, potentially causing structural damage, spinal deformity, and disability.
Prevalence: The Prevalence of AS in China is approximately 0.36%, affecting over 5 million individuals. Demographics: AS predominantly affects males aged between 15–40, with onset typically occur before the age of 35. Pathogenesis: The pathogenesis of AS is linked to genetic, infectious, environmental, and immunological factors. The disease progresses over time, often resulting in irreversible damage. Treatment: JAK inhibitors, as non-immunogenic small-molecule drugs, avoid secondary failure caused by neutralizing antibodies (common with biologics), offering a promising therapeutic approach.
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn